MedTrace Logo

Targeting Anhedonia in Cocaine Use Disorder

NCT02773212 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-08-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine anhedonia as a potential moderator of treatment outcomes for Cocaine Use Disorder (CUD). Specifically, this study will investigate how anhedonia affects outcomes in contingency management (CM) treatment for CUD and whether anhedonia mediates the effects of adjunctive treatment with a dopaminergic (DAergic) drug, d-amphetamine, on outcomes in CM for CUD, as well as investigate the contribution of anhedonia to overall CUD severity.

Conditions

  • Cocaine-Related Disorders
  • Anhedonia

Interventions

DRUG

d-amphetamine

Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.

BEHAVIORAL

Contingency management

Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.

DRUG

Placebo (for d-amphetamine)

60 mg of riboflavin and cornstarch as needed.

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    collaborator OTHER

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Margaret C Wardle, Ph.D. · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2022-04-04
Completion
2022-04-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02773212 on ClinicalTrials.gov